Belzutifan special drug use results survey in von Hippel-Lindau (VHL) disease-associated tumors: a post-authorization safety study (PASS) (MK-6482-046)

20/02/2026
20/02/2026
EU PAS number:
EUPAS1000000881
Study
Planned
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

6482-046-01-v0-with-ha-approval-date_final-redaction.pdf

English (527.14 KB - PDF) View document
Study results
Study report
Other information